While it may not be possible for clinical trials to go completely virtual with AI, there are big cost and efficiency advantages to applying artificial intelligence to them.
Biogen‘s made headlines of late for committing $2.5 billion on a Alzheimer’s drug development gamble – and, notably, preparing for a return to the ALS market. Making such broad commitments can stir a lot of hope up among a desperate patient base – something CEO George Scangos has learned a lesson or two about by now. Two years ago, Biogen famously halted Phase 3 […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Partners Healthcare just released a list of what it ranks the top dozen most promising approaches in neurocare. Here’s that dozen, populated with useful links that inform the direction academia – and business – are headed. They’ve been vetted, and it’s confirmed: These trends truly are on the bleeding edge of research. Many of these applications […]
We’ll be skiing at 95, living well past 125 – with our brains controlling machinery that’s symbiotic with our bodies. Or so said Geoffrey Ling, director of the biological technologies office at DARPA. He spoke about the sci-fi future of neuroscience while on a panel this week at the World Medical Innovation Forum in Boston. Ling was joined by Ajay Verma, […]